Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CITIZENS FINANCIAL GROUP INC/RICFG · Entity 1913 | Director | February 14, 2019 | February 15, 2019 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | July 02, 2026 | July 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CITIZENS FINANCIAL GROUP INC/RI
Report date February 14, 2019 · Filed February 15, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,993.604 |
Reported balance
After 2019-02-14 transaction · row 1
1 source rowRow 1 · 2019-02-14 · Grant · Acquired 30.91 · Balance 60,993.604 F1: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan.
REGENERON PHARMACEUTICALS, INC.
Report date July 02, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,303 |
Reported balance
After 2026-07-02 transaction · row 1
1 source rowRow 1 · 2026-07-02 · Sale · Disposed 200 · Balance 17,303 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F2: Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025.
F2: Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2023 Filed Dec 4, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $821.92 | $1,643.84 |
DisclosureSEC source: 0001968202-23-000044 · edgardoc.xml · nonDerivative · entry 13 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,471 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9 | $820.50 | $7,384.50 |
DisclosureSEC source: 0001968202-23-000044 · edgardoc.xml · nonDerivative · entry 12 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,473 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F11 · price: Represents volume-weighted average price of sales of 9 shares of Company stock on December 1, 2023 at prices ranging from $820.02 to $820.71. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2023 at each separate price. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $819.62 | $5,737.34 |
DisclosureSEC source: 0001968202-23-000044 · edgardoc.xml · nonDerivative · entry 11 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,482 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F10 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on December 1, 2023 at prices ranging from $819.03 to $819.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2023 at each separate price. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $818.76 | $1,637.52 |
DisclosureSEC source: 0001968202-23-000044 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,489 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F9 · price: Represents volume-weighted average price of sales of 2 shares of Company stock on December 1, 2023 at prices ranging from $818.53 to $818.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2023 at each separate price. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $817.52 | $4,905.12 |
DisclosureSEC source: 0001968202-23-000044 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,491 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F8 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on December 1, 2023 at prices ranging from $817.06 to $817.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2023 at each separate price. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $816.52 | $3,266.08 |
DisclosureSEC source: 0001968202-23-000044 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,497 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F7 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on December 1, 2023 at prices ranging from $816.26 to $816.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2023 at each separate price. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $815.46 | $2,446.38 |
DisclosureSEC source: 0001968202-23-000044 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,501 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F6 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on December 1, 2023 at prices ranging from $815.21 to $815.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2023 at each separate price. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $814.78 | $814.78 |
DisclosureSEC source: 0001968202-23-000044 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,504 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $813.35 | $3,253.40 |
DisclosureSEC source: 0001968202-23-000044 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,505 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F5 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on December 1, 2023 at prices ranging from $813.02 to $813.70. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2023 at each separate price. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $812.58 | $2,437.74 |
DisclosureSEC source: 0001968202-23-000044 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,509 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F4 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on December 1, 2023 at prices ranging from $812.31 to $812.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2023 at each separate price. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 27 | $811.48 | $21,909.96 |
DisclosureSEC source: 0001968202-23-000044 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,512 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F3 · price: Represents volume-weighted average price of sales of 27 shares of Company stock on December 1, 2023 at prices ranging from $811.08 to $811.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2023 at each separate price. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $810.77 | $5,675.39 |
DisclosureSEC source: 0001968202-23-000044 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,539 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F2 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on December 1, 2023 at prices ranging from $810.47 to $810.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2023 at each separate price. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $809.03 | $809.03 |
DisclosureSEC source: 0001968202-23-000044 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,546 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| November 07, 2023 Filed Nov 8, 2023 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $838.46 | $838.46 |
DisclosureSEC source: 0001968202-23-000039 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,547 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| November 07, 2023 Filed Nov 8, 2023 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $830.39 | $2,491.17 |
DisclosureSEC source: 0001968202-23-000039 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,548 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F8 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on November 7, 2023 at prices ranging from $830.04 to $830.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 7, 2023 at each separate price. Read SEC document |
| November 07, 2023 Filed Nov 8, 2023 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 18 | $829.43 | $14,929.74 |
DisclosureSEC source: 0001968202-23-000039 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,551 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F7 · price: Represents volume-weighted average price of sales of 18 shares of Company stock on November 7, 2023 at prices ranging from $829.10 to $829.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 7, 2023 at each separate price. Read SEC document |
| November 07, 2023 Filed Nov 8, 2023 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 39 | $828.54 | $32,313.06 |
DisclosureSEC source: 0001968202-23-000039 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,569 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F6 · price: Represents volume-weighted average price of sales of 39 shares of Company stock on November 7, 2023 at prices ranging from $828.01 to $828.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 7, 2023 at each separate price. Read SEC document |
| November 07, 2023 Filed Nov 8, 2023 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 11 | $827.65 | $9,104.15 |
DisclosureSEC source: 0001968202-23-000039 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,608 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F5 · price: Represents volume-weighted average price of sales of 11 shares of Company stock on November 7, 2023 at prices ranging from $827.03 to $827.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 7, 2023 at each separate price. Read SEC document |
| November 07, 2023 Filed Nov 8, 2023 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $826.58 | $3,306.32 |
DisclosureSEC source: 0001968202-23-000039 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,619 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F4 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on November 7, 2023 at prices ranging from $826.44 to $826.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 7, 2023 at each separate price. Read SEC document |
| November 07, 2023 Filed Nov 8, 2023 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 18 | $825.53 | $14,859.54 |
DisclosureSEC source: 0001968202-23-000039 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,623 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F3 · price: Represents volume-weighted average price of sales of 18 shares of Company stock on November 7, 2023 at prices ranging from $825.04 to $825.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 7, 2023 at each separate price. Read SEC document |
| November 07, 2023 Filed Nov 8, 2023 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $824.59 | $4,947.54 |
DisclosureSEC source: 0001968202-23-000039 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,641 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F2 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on November 7, 2023 at prices ranging from $824.14 to $824.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 7, 2023 at each separate price. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:25 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $744.66 | $744.66 |
DisclosureSEC source: 0001883850-23-000075 · edgardoc.xml · nonDerivative · entry 11 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,647 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:25 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $741.42 | $1,482.84 |
DisclosureSEC source: 0001883850-23-000075 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,648 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:25 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $740.52 | $2,221.56 |
DisclosureSEC source: 0001883850-23-000075 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,650 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:25 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $739.63 | $3,698.15 |
DisclosureSEC source: 0001883850-23-000075 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,653 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. F9 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on August 1, 2023 at prices ranging from $739.40 to $739.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2023 at each separate price. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:25 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10 | $738.45 | $7,384.50 |
DisclosureSEC source: 0001883850-23-000075 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,658 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. F8 · price: Represents volume-weighted average price of sales of 10 shares of Company stock on August 1, 2023 at prices ranging from $738.02 to $738.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2023 at each separate price. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:25 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 17 | $737.50 | $12,537.50 |
DisclosureSEC source: 0001883850-23-000075 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,668 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. F7 · price: Represents volume-weighted average price of sales of 17 shares of Company stock on August 1, 2023 at prices ranging from $737.04 to $737.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2023 at each separate price. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:25 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 16 | $736.64 | $11,786.24 |
DisclosureSEC source: 0001883850-23-000075 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,685 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. F6 · price: Represents volume-weighted average price of sales of 16 shares of Company stock on August 1, 2023 at prices ranging from $736.05 to $736.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2023 at each separate price. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:25 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 22 | $735.55 | $16,182.10 |
DisclosureSEC source: 0001883850-23-000075 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,701 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. F5 · price: Represents volume-weighted average price of sales of 22 shares of Company stock on August 1, 2023 at prices ranging from $735.01 to $735.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2023 at each separate price. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:25 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 18 | $734.56 | $13,222.08 |
DisclosureSEC source: 0001883850-23-000075 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,723 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. F4 · price: Represents volume-weighted average price of sales of 18 shares of Company stock on August 1, 2023 at prices ranging from $734.04 to $734.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2023 at each separate price. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:25 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $733.51 | $2,934.04 |
DisclosureSEC source: 0001883850-23-000075 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,741 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. F3 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on August 1, 2023 at prices ranging from $733.10 to $733.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2023 at each separate price. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:25 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $732.76 | $1,465.52 |
DisclosureSEC source: 0001883850-23-000075 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,745 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. F2 · price: Represents volume-weighted average price of sales of 2 shares of Company stock on August 1, 2023 at prices ranging from $732.70 to $732.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2023 at each separate price. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $720.15 | $720.15 |
DisclosureSEC source: 0001968202-23-000016 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,747 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 11 | $719.36 | $7,912.96 |
DisclosureSEC source: 0001968202-23-000016 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,748 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. F7 · price: Represents volume-weighted average price of sales of 11 shares of Company stock on July 3, 2023 at prices ranging from $719.05 to $719.56. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 3, 2023 at each separate price. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 12 | $718.71 | $8,624.52 |
DisclosureSEC source: 0001968202-23-000016 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,759 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. F6 · price: Represents volume-weighted average price of sales of 12 shares of Company stock on July 3, 2023 at prices ranging from $718.47 to $718.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 3, 2023 at each separate price. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 22 | $717.57 | $15,786.54 |
DisclosureSEC source: 0001968202-23-000016 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,771 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. F5 · price: Represents volume-weighted average price of sales of 22 shares of Company stock on July 3, 2023 at prices ranging from $717.22 to $717.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 3, 2023 at each separate price. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 29 | $716.74 | $20,785.46 |
DisclosureSEC source: 0001968202-23-000016 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,793 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. F4 · price: Represents volume-weighted average price of sales of 29 shares of Company stock on July 3, 2023 at prices ranging from $716.09 to $716.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 3, 2023 at each separate price. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $715.23 | $5,006.61 |
DisclosureSEC source: 0001968202-23-000016 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,822 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. F3 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on July 3, 2023 at prices ranging from $715.02 to $715.70. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 3, 2023 at each separate price. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10 | $714.65 | $7,146.50 |
DisclosureSEC source: 0001968202-23-000016 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,829 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. F2 · price: Represents volume-weighted average price of sales of 10 shares of Company stock on July 3, 2023 at prices ranging from $714.17 to $714.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 3, 2023 at each separate price. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $713.82 | $4,282.92 |
DisclosureSEC source: 0001968202-23-000016 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,839 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $711.95 | $711.95 |
DisclosureSEC source: 0001968202-23-000016 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,845 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $710.09 | $710.09 |
DisclosureSEC source: 0001968202-23-000016 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,846 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $738.35 | $5,168.45 |
DisclosureSEC source: 0001883850-23-000073 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,847 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. F8 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on June 1, 2023 at prices ranging from $738.13 to $738.67. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 1, 2023 at each separate price. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 17 | $737.52 | $12,537.84 |
DisclosureSEC source: 0001883850-23-000073 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,854 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. F7 · price: Represents volume-weighted average price of sales of 17 shares of Company stock on June 1, 2023 at prices ranging from $737.00 to $737.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 1, 2023 at each separate price. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 31 | $736.40 | $22,828.40 |
DisclosureSEC source: 0001883850-23-000073 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,871 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. F6 · price: Represents volume-weighted average price of sales of 31 shares of Company stock on June 1, 2023 at prices ranging from $736.00 to $736.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 1, 2023 at each separate price. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 12 | $735.42 | $8,825.04 |
DisclosureSEC source: 0001883850-23-000073 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,902 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. F5 · price: Represents volume-weighted average price of sales of 12 shares of Company stock on June 1, 2023 at prices ranging from $735.00 to $735.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 1, 2023 at each separate price. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10 | $734.62 | $7,346.20 |
DisclosureSEC source: 0001883850-23-000073 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,914 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. F4 · price: Represents volume-weighted average price of sales of 10 shares of Company stock on June 1, 2023 at prices ranging from $734.15 to $734.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 1, 2023 at each separate price. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $733.61 | $1,467.22 |
DisclosureSEC source: 0001883850-23-000073 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,924 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10 | $732.49 | $7,324.90 |
DisclosureSEC source: 0001883850-23-000073 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,926 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. F3 · price: Represents volume-weighted average price of sales of 10 shares of Company stock on June 1, 2023 at prices ranging from $732.10 to $732.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 1, 2023 at each separate price. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9 | $731.49 | $6,583.41 |
DisclosureSEC source: 0001883850-23-000073 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,936 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. F2 · price: Represents volume-weighted average price of sales of 9 shares of Company stock on June 1, 2023 at prices ranging from $731.23 to $731.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 1, 2023 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.